Shape-dependent adjuvanticity of nanoparticle-conjugated RNA adjuvants for intranasal inactivated influenza vaccines

Intranasal inactivated influenza vaccines can elicit mucosal immune responses that protect against virus infection. For the development of intranasal inactivated influenza vaccines, effective adjuvants inducing minimal adverse reactions are required. Generally, however, lower toxicity adjuvants have...

Full description

Saved in:
Bibliographic Details
Published in:RSC advances Vol. 8; no. 30; pp. 16527 - 16536
Main Authors: Tazaki, Taiyu, Tabata, Koshiro, Ainai, Akira, Ohara, Yuki, Kobayashi, Shintaro, Ninomiya, Takafumi, Orba, Yasuko, Mitomo, Hideyuki, Nakano, Tetsuo, Hasegawa, Hideki, Ijiro, Kuniharu, Sawa, Hirofumi, Suzuki, Tadaki, Niikura, Kenichi
Format: Journal Article
Language:English
Published: England Royal Society of Chemistry 01-01-2018
The Royal Society of Chemistry
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Intranasal inactivated influenza vaccines can elicit mucosal immune responses that protect against virus infection. For the development of intranasal inactivated influenza vaccines, effective adjuvants inducing minimal adverse reactions are required. Generally, however, lower toxicity adjuvants have lower adjuvanticity. In this research, we fabricated nanoparticle-based adjuvants to enhance its adjuvanticity. Herein, we focused on low-molecular-weight polyinosinic-polycytidylic acid, referred to as uPIC(40:400), as a weak and less toxic RNA adjuvant. We conjugated uPIC(40:400) with different shaped gold nanoparticles (AuNPs) electrostatically. Conjugation with gold nanorods, but not spherical AuNPs, markedly enhanced the adjuvanticity of uPIC(40:400), leading to the suppression of viral infection in mice. Notably, conjugation with gold nanorods did not increase the inflammatory cytokine production in dendritic cells. These data indicated that gold nanorods can provide a good platform for enhancing the weak adjuvanticity of uPIC(40:400) while maintaining low inflammatory cytokine production toward the development of intranasal inactivated influenza vaccines.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2046-2069
2046-2069
DOI:10.1039/c8ra01690a